Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Legal Briefs: AstraZeneca Wins Seroquel Suit, King Settles With DoJ, Sanofi Resolves Gender Discrimination Suit

Executive Summary

AstraZeneca wins first Seroquel product liability trial: A New Jersey state court jury reached a verdict in favor of AstraZeneca, rejecting a plaintiff's claims that the antipsychotic caused his diabetes. The case, Baker v. AstraZeneca, is the first to go to trial. AstraZeneca is facing more than 14,000 Seroquel (quetiapine) lawsuits involving more than 22,000 plaintiffs alleging the company failed to adequately warn of the risk of diabetes. Nine previous cases set for trial were dismissed. The company said that in these cases and in the Baker suit, the facts showed that the plaintiffs either already had diabetes or had so many pre-existing risk factors that they had a significantly increased risk of diabetes before taking Seroquel

Related Content

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

PS052050

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel